Continuing this line of investigation with a focus on the molecular mechanism whereby BRG1 regulates SREBP2 activity will hopefully solidify the role of BRG1 leading to a rationalized decision to target BRG1 in the intervention of NASH. Here, SMARCA4 is linked to metabolic dysfunction-associated steatohepatitis.